|
Silver News
Clinical Experiments Show Silver Compound Can Help AIDS Patients:
Researchers Say Silver Oxide Offsets AIDS Loss of Immune Response
By Samuel Etris, Senior Technical Consultant
to The Silver Institute
One dose of silver oxide may prolong the life of terminally
ill patients suffering from AIDS, according to a study conducted
at an AIDS clinic in Central America. The triple-charged silver
in silver oxide appears to significantly increase the effectiveness
of silver in combating disease-prone bacteria and viruses
that rage through an AIDS-infected patient. This action of
silver offsets the loss of the body's bacteria-fighting immune
system caused by the AIDS virus.
The ten patients classified as terminally
ill at The Struggle Against AIDS Clinic, Comayaguela, Honduras,
were treated with polyvalent silver oxide. The ten patients
fell into two of the major AIDS categories: Wasting Syndrome
and Candidasis, which covers approximately one third of all
AIDS cases.
Before the administration of one single dose
of polyvalent silver oxide (approximately 40 parts per million
of blood volume), the patients were removed from the standard
AZT therapy. Following the administration of polyvalent silver
oxide, eight out of nine patients showed an increase in their
white blood count from 10 to 350 percent. Then they were treated
with the standard antibiotics.
Two of the patients had conditions so far
advanced that they were unresponsive to the subsequent treatment
and succumbed within a year. However, the single treatment
appeared to prolong the lives of the eight remaining patients
as much as three years. This single experiment shows the promise
for the polyvalent silver oxide regimen.
Further research is needed to investigate
the optimal modes of administration and dosages of the polyvalent
silver oxide for AIDS therapy. Additional clinical trials
are now being organized in South Africa to gain more data
on its potential.
For more than a century, single-charged silver
has been a proven barrier against blindness in babies' eyes
exposed to disease during birth. The single-charged silver
replaces the working hydrogen atoms of bacteria and extracellular
viruses that supply the energy to function. Blocking the energy
supply inactivates them. The more powerful triple-charged
silver in polyvalent silver oxide signals new potential in
combating disease.
In one laboratory experiment, polyvalent
silver oxide in as little a concentration as 20 parts per
million inserted into cultured HIV-1 infected cells resulted
in a 98.4-percent kill. This breakthrough, reported by the
National Virology Laboratory of Israel at Tel HaShomer, encouraged
the Kaplan Hospital, Rehovot, Israel, to conduct a study of
laboratory mice infected with Murine AIDS. A single administration
of 40 parts per million of polyvalent silver oxide (Ag4O4)
reportedly resulted in an effective cure.
These early experiments with AIDS infections
indicate that polyvalent silver oxide may be more than merely
a multi-spectrum antibiotic inactivating a whole range of
bacteria, such as candida albicans, that ravage the AIDS-weakened
immune system. Further studies may reveal that silver also
stimulates the body's immune system to restore at least some
of its normal function, aiding in the patient's recovery.
For nearly a decade, Antelman Technologies,
Inc., Rehovot, Israel, has been conducting laboratory and
clinical studies to determine the effectiveness of polyvalent
silver oxide for a wide variety of applications. Currently
it is available over the counter as the EPA-approved product
Sildate, which replaces chlorine in swimming pools,
U.S. patents for which have been assigned to the supplier,
N. Jonas & Co. in Bensalem, Pennsylvania.
The buffer to bring polyvalent silver oxide
into an injectable solution for clinical evaluation is supplied
by Holipharm Corp., in Jerusalem, which has received the assignment
of all rights of U.S. patents for (Ag4O4) AIDS studies under
the trade name Tetrasil.
Silver News - February/March 1998
|
